Interview with Derek Williams, Vice President and General Manager, Vifor Pharma…
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
Address: The Old Stables, Bagshot Park, Bagshot, Surrey GU19 5PJ, United Kingdom
Tel: +44 (0) 1276 853 600
Web: http://www.viforpharma.com/en/
Vifor Pharma UK is an affiliate of the Vifor Pharma, the pharma business sector of the Galenica Group. Vifor Pharma, the Pharma business sector of the Galenica Group, is an internationally active company, which researches, develops, manufactures and markets pharmaceutical products worldwide. Galenica is a diversified group active throughout the healthcare market which among other things, develops manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks.
Vifor Pharma UK focuses its activities on iron deficiency anaemia, a globally widespread ailment. It develops and manufactures iron replacement pharmaceutical products. These products are:
• Ferinject
• Venofer
You joined Vifor Pharma to establish a new structure in the UK. It is quite difficult to set up a new enterprise—what have been the main challenges for yourself and…
A roundup of the biggest UK pharma news, including the industry’s uncertain position after the UK-US trade accord; Haleon’s full takeover of its Chinese joint venture; AstraZeneca’s acquisition of Belgian…
UK Prime Minister Keir Starmer’s government continues its push to overhaul the country’s iconic National Health Service (NHS). After originally announcing plans to restructure NHS England, the body that manages…
Dr Carolyn H. Rogers, Rushikesh S. Dasoondi and Dr Michael A. Roberts from UK and European intellectual property law firm Reddie & Grose LLP examine the intersection of personalised medicine…
Fiona Carragher, Chief Policy and Research Officer at Alzheimer’s Society, delves into the organization’s mission to transform dementia care through innovation, advocacy, and global collaboration. Carragher addresses critical challenges, including…
Seen by most as life-sciences friendly, the UK Government’s 2024 Autumn Budget not only pledges to increase funding for the country’s ailing National Health Service (NHS), but to dedicate additional…
The participation of Emma Walmsley, CEO of GlaxoSmithKline (GSK), in the FT Live Global Pharma and Biotech Summit coincided with the outcome of the American elections and the historic win…
A roundup of top stories from UK pharma and healthcare, including the innovative manufacturing fund comprised in the government’s new life-sciences-focused budget; GSK’s autoimmune therapy deal with Chimagen Biosciences; Northern…
Medtech-focused recruitment consultant Ivor Campbell casts his eye over the profiles the global medtech industry needs most today. Campbell argues that while specialist scientists and engineers remain as important as…
The newly elected UK government’s Secretary of State for Health and Social Care Wes Streeting has a full plate of challenges ahead. Britain’s National Health Service (NHS) is plagued with…
Throughout his long career, John-Arne Rottingen has gathered experience across multiple domains from discovery research to public health and diplomacy that led him to become the founding CEO of the…
A roundup of some of the biggest stories coming out of the UK pharma industry, including AstraZeneca’s bid for cancer specialist Fusion Pharmaceuticals; the shutdown of Sanofi’s R&D site in…
Last year the UK-based pharma industry warned against the country’s waning competitiveness, condemning the government’s statutory scheme designed to control drug prices. UK-headquartered AstraZeneca joined the battle cry, claiming it…
See our Cookie Privacy Policy Here
